Journal
MEDICINE
Volume 97, Issue 36, Pages -Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MD.0000000000012207
Keywords
chemotherapy; clival chordoma; gamma knife radiosurgery; maximally safe cyto-reductive resection; multimodal treatment; radiosurgery
Categories
Funding
- Foundation of Health Department of Jiangxi Province [2016A073]
- Foundation of the Graduate Innovation Center, Jiangxi Province, China [YC2017-S097]
- Gan-Po Talents Project 555 of Jiangxi Province
Ask authors/readers for more resources
The treatment of clival chordoma remains highly challenging. This difficulty is enhanced by the very small likelihood of a successful complete surgical resection or nonsurgical treatment of chordoma. Additionally, no effective means of interdisciplinary treatment for chordoma have been identified. With this background, we analyzed data of patients who underwent multidisciplinary treatment for clival chordoma at our institution during the last 25 years. This retrospective study evaluated patients treated at a single center from 1992 to 2017. During the study period, 24 patients underwent 24 surgeries. Twenty-two surgical resections (including 1 initial surgery and 1 surgery for recurrence) were deemed maximally safe cyto-reductive resections (92%); the remaining 2 surgeries were deemed incomplete (8%), which were histologically confirmed in all but in 1 case (which involved radionecrosis). The complications were divided into endocrinologic, neurologic, and other complications. In 1 case (4%), surgery led to immediate dyspnea followed by death on the following day; in another case (4%), ischemic infarction led to sudden death. In 3 cases (13%), patients exhibited improvements of neurologic (visual or oculomotor) deficits that had been observed prior to surgery. The following new postoperative neurologic deficits were observed: oculomotor deficits in 4 cases, dizziness in 2 cases, and cranial nerve-attributed dysphagia in 3 cases. About 19 patients underwent adjuvant postoperative radiotherapy following the initial surgery (dose: 54.5 Gy in all cases). The mean and median follow-up durations were 50 +/- 53 and 48.5 months, respectively. A Kaplan-Meier analysis estimated a median survival duration of 50.2 months (95% confidence interval 27.9-72.4 months). These findings highlight the importance of interdisciplinary treatment strategies, particularly those combining maximally safe cytoreductive tumor resection and adjusted radiotherapy and other treatment options, for patients with relatively good conditions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available